| Feb-04-19 07:30AM | Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist PR Newswire |
| Jan-23-19 07:22AM | The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga |
| 03:00AM | Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy PR Newswire |
| Jan-07-19 03:00AM | Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China PR Newswire |
| Jan-03-19 07:30AM | Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.34% |
| Dec-17-18 07:08PM | Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire |
| Dec-12-18 10:56PM | Biohaven Announces Pricing of Public Offering of Common Shares PR Newswire |
| Dec-10-18 07:19PM | Biohaven Announces Proposed Public Offering of Common Shares PR Newswire |
| 03:00AM | Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study PR Newswire |
| Dec-03-18 03:00AM | Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine PR Newswire +25.39% |
| Nov-29-18 08:09AM | The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga |
| Nov-28-18 04:00PM | Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary PR Newswire |
| Nov-27-18 08:35AM | Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes New Research Emphasizes Economic Growth GlobeNewswire -7.69% |
| Nov-26-18 03:00AM | Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire |
| Nov-20-18 03:00AM | Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018 PR Newswire |
| Nov-15-18 03:00AM | Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant PR Newswire |
| Nov-14-18 04:06PM | Migraine-Focused Biotech Has A Headache On Quarterly Losses Investor's Business Daily -8.73% |
| 03:00AM | Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results PR Newswire |
| Nov-13-18 08:30AM | Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies PR Newswire |
| Oct-22-18 03:00AM | Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist PR Newswire |
| Oct-10-18 02:42PM | Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Oct-09-18 03:00AM | Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut PR Newswire |
| Sep-12-18 06:19AM | Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine PR Newswire +6.40% |
| 03:00AM | Biohaven Appoints Bob Repella to Board of Directors PR Newswire |
| Sep-06-18 03:00AM | Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine PR Newswire |
| Sep-05-18 08:28AM | The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga |
| 03:00AM | Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy PR Newswire |
| Aug-16-18 09:37AM | The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga +5.95% |
| Aug-14-18 04:15PM | Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results PR Newswire |
| Aug-01-18 07:35AM | Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services New Research Emphasizes Economic Growth GlobeNewswire |
| 03:00AM | First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial PR Newswire |
| Jul-31-18 07:15AM | Free Stock Performance Review on Biogen and Three Additional Biotech Stocks ACCESSWIRE |
| Jul-24-18 03:00AM | Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease PR Newswire |
| Jun-28-18 12:30PM | Biohaven Pharma's New Migraine Drug Shows Promise in Late-Stage Test Results TheStreet.com |
| 07:20AM | Free Technical Reports on Cerus and Three Additional Biotech Equities ACCESSWIRE |
| 03:00AM | Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting PR Newswire |
| Jun-21-18 07:15AM | Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma ACCESSWIRE |
| Jun-19-18 08:37AM | Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Is Expected To Breakeven Simply Wall St. |
| Jun-18-18 08:06PM | Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million PR Newswire |
| Jun-13-18 07:30AM | Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region PR Newswire |
| Jun-05-18 03:00AM | Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018 PR Newswire |
| May-16-18 08:35AM | What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltds (NYSE:BHVN) Earnings Trend? Simply Wall St. |
| May-15-18 04:15PM | Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results PR Newswire |
| May-09-18 07:35AM | Our Free Research Report on Biogen and More Biotech Stocks ACCESSWIRE |
| 03:00AM | Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire |
| Apr-22-18 10:00PM | Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine PR Newswire |
| Apr-19-18 07:45AM | Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon Enterprise, Tutor Perini, Waste Management, and Twenty-First Century Fox New Research Emphasizes Economic Growth GlobeNewswire |
| 03:00AM | Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles PR Newswire |
| Apr-05-18 09:52AM | Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference PR Newswire |
| Apr-03-18 03:00AM | Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer PR Newswire |
| Mar-28-18 07:40AM | Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant ACCESSWIRE +8.18% |
| Mar-27-18 04:34PM | Canaccord Sees An 'Intriguing Setup' In Biohaven Following Reaction To Phase 3 News Benzinga |
| 06:47AM | Heres Whats Moving AnaptysBio and Biohaven Pharmaceutical Market Exclusive |
| Mar-26-18 04:13PM | Biohaven Craters By A Third On Migraine Drug Study Rivaling Allergan Investor's Business Daily -7.27% |
| 12:31PM | Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today Motley Fool |
| 12:19PM | Biohaven's IPO Roadshow Fantasy Meets Grimmer Reality Bloomberg |
| 11:15AM | Biohaven plunges as investors pit migraine data against Allergan's drug Reuters |
| 09:05AM | Biohaven shares drop 23% after migraine drug trial results MarketWatch |
| 03:00AM | Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire |
| Mar-20-18 07:50PM | Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN): Is Breakeven Near? Simply Wall St. |
| Mar-13-18 10:42AM | Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options Zacks |
| Mar-12-18 03:00AM | Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors PR Newswire |
| Mar-06-18 04:30PM | Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial And Business Results PR Newswire -7.59% |
| 03:00AM | Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine PR Newswire |
| Mar-01-18 03:00AM | Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet PR Newswire |
| Feb-21-18 03:00AM | Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists PR Newswire |
| Feb-08-18 07:40AM | Analysis: Positioning to Benefit within Great Plains Energy, Flowers Foods, Hasbro, BIOHAVEN PHARM, Vonage, and NOW Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -6.58% |
| Feb-01-18 07:35AM | Investor Expectations to Drive Momentum within Park National, Loral Space and Communications, Allegiance Bancshares, BIOHAVEN PHARM, Equifax, and PayPal Discovering Underlying Factors of Influence GlobeNewswire -5.38% |
| Jan-18-18 03:00AM | Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist PR Newswire +7.58% |
| Jan-11-18 07:40AM | Wired News Biohaven Pharmaceutical Shares Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally Dissolving Tablet ACCESSWIRE |
| Jan-09-18 03:00AM | Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet PR Newswire |
| Dec-21-17 03:00AM | Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder PR Newswire |
| Nov-27-17 03:00AM | Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant PR Newswire |
| Nov-20-17 07:40AM | Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE |
| 03:00AM | Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine PR Newswire |
| Nov-16-17 03:00AM | Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine PR Newswire +5.93% |
| Nov-14-17 06:02PM | Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results PR Newswire |
| Nov-13-17 03:00AM | Biohaven Expands Finance Team With Appointment Of Senior Vice President PR Newswire |
| Nov-06-17 03:00AM | Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 PR Newswire |
| Nov-01-17 04:00AM | Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with ALS Benzinga |
| 03:00AM | Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire |
| Oct-30-17 03:00AM | Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute PR Newswire |
| Oct-26-17 07:30AM | Corporate News Blog - US FDA Green Signals Clinical Investigation of Biohaven Pharma's Trigriluzole For Treatment Of OCD ACCESSWIRE |
| Oct-25-17 03:00AM | Biohaven Adds Clifford Bechtold as Chief Operating Officer PR Newswire |
| Oct-24-17 03:00AM | Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder PR Newswire |
| Oct-03-17 04:25PM | Why This Biotech Suffered A 2-Day Headache On Rare-Disease Trial Investor's Business Daily -6.97% |
| Oct-02-17 12:24PM | Here's Why Biohaven Pharmaceutical Stock Fell as Much as 28.6% Today Motley Fool |
| 06:30AM | Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial PR Newswire |
| Sep-15-17 03:00AM | Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease PR Newswire |
| Sep-11-17 03:00AM | Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference PR Newswire |
| Aug-30-17 07:30AM | [$$] Zinsli's Take: A Milestone for Post-IPO Companies Is In Sight The Wall Street Journal |
| Aug-14-17 06:44AM | Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results PR Newswire |
| Aug-07-17 03:00AM | Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 PR Newswire |
| Aug-04-17 03:00AM | Biohaven Appoints Julia P. Gregory to Board of Directors PR Newswire |
| Jul-31-17 03:00AM | Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine PR Newswire |
| Jul-24-17 03:00AM | Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine PR Newswire |
| Jul-18-17 03:00AM | PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology PR Newswire |
| Jul-13-17 03:00AM | Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs PR Newswire |
| Jul-12-17 09:50AM | IPO Market Back On Track: ETFs to Tap Zacks |
| Jul-09-17 12:22PM | [$$] Clinical Development News, July 3-7 The Wall Street Journal |
|
|
|
| Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| AGUIAR ERIC | Director | Feb 04 | Option Exercise | 23.47 | 17,609 | 413,291 | 17,609 | Feb 06 06:21 PM | | Tilton John | Chief Commercial Officer | Jan 10 | Option Exercise | 9.29 | 10,500 | 97,545 | 10,500 | Jan 14 05:50 PM | | Tilton John | Chief Commercial Officer | Jan 10 | Sale | 37.67 | 10,500 | 395,535 | 0 | Jan 14 05:50 PM | | Doogan Declan | Director | Dec 03 | Sale | 41.95 | 40,000 | 1,678,000 | 1,156,002 | Dec 06 04:26 PM | | Gentile Kimberly | VP of Operations | Jun 15 | Option Exercise | 0.61 | 12,500 | 7,625 | 12,500 | Jun 19 04:43 PM | | Gentile Kimberly | VP of Operations | Jun 15 | Sale | 40.02 | 12,500 | 500,250 | 0 | Jun 19 04:43 PM | | Berman Robert | Chief Medical Officer | Jun 12 | Sale | 37.39 | 20,257 | 757,443 | 234,551 | Jun 12 04:12 PM | | Berman Robert | Chief Medical Officer | Jun 11 | Sale | 36.09 | 75,492 | 2,724,160 | 250,827 | Jun 12 04:12 PM | | Berman Robert | Chief Medical Officer | Jun 08 | Sale | 36.01 | 8,406 | 302,700 | 320,692 | Jun 12 04:12 PM | | Berman Robert | Chief Medical Officer | Jun 07 | Sale | 36.01 | 2,500 | 90,025 | 327,427 | Jun 07 04:29 PM | | Berman Robert | Chief Medical Officer | Jun 06 | Sale | 36.01 | 16,983 | 611,558 | 329,430 | Jun 07 04:29 PM | | Berman Robert | Chief Medical Officer | Jun 05 | Sale | 36.02 | 6,362 | 229,131 | 343,038 | Jun 07 04:29 PM | | Doogan Declan | Director | Jun 05 | Sale | 35.41 | 49,763 | 1,762,285 | 1,196,002 | Jun 06 04:19 PM | | Doogan Declan | Director | Jun 04 | Sale | 35.05 | 39,453 | 1,382,828 | 1,245,765 | Jun 06 04:19 PM | | Doogan Declan | Director | Jun 01 | Sale | 35.04 | 83,898 | 2,939,786 | 1,285,218 | Jun 01 05:29 PM | | Coric Vlad | Chief Executive Officer | Jun 01 | Sale | 35.04 | 13,840 | 484,954 | 525,000 | Jun 01 05:26 PM | | Doogan Declan | Director | May 31 | Sale | 35.01 | 26,044 | 911,800 | 1,369,116 | Jun 01 05:29 PM | | Coric Vlad | Chief Executive Officer | May 31 | Sale | 35.01 | 34,619 | 1,212,011 | 530,229 | Jun 01 05:26 PM | | Engelhart James | Chief Financial Officer | May 30 | Option Exercise | 0.61 | 5,000 | 3,050 | 5,000 | May 30 06:02 PM | | Doogan Declan | Director | May 30 | Sale | 35.00 | 842 | 29,470 | 1,395,160 | Jun 01 05:29 PM | | Coric Vlad | Chief Executive Officer | May 30 | Sale | 35.00 | 1,541 | 53,935 | 549,200 | Jun 01 05:26 PM | | Engelhart James | Chief Financial Officer | May 30 | Sale | 35.00 | 5,000 | 175,000 | 0 | May 30 06:02 PM | | Berman Robert | Chief Medical Officer | May 10 | Sale | 26.82 | 35,000 | 938,706 | 348,000 | May 14 05:11 PM | | Engelhart James | Chief Financial Officer | May 07 | Sale | 27.67 | 2,500 | 69,175 | 0 | May 09 04:53 PM | | Berman Robert | Chief Medical Officer | Apr 10 | Sale | 24.66 | 35,000 | 863,132 | 376,000 | Apr 12 05:02 PM | | Berman Robert | Chief Medical Officer | Mar 12 | Sale | 30.11 | 35,000 | 1,053,929 | 404,000 | Mar 14 05:05 PM | | Gentile Kimberly | VP of Operations | Mar 01 | Option Exercise | 0.61 | 5,000 | 3,050 | 5,000 | Mar 05 04:31 PM | | Gentile Kimberly | VP of Operations | Mar 01 | Sale | 32.87 | 5,000 | 164,344 | 0 | Mar 05 04:31 PM | | Engelhart James | Chief Financial Officer | Feb 21 | Sale | 29.60 | 538 | 15,925 | 3,038 | Feb 23 05:52 PM |
|
